News headlines about Ascendis Pharma A/S (NASDAQ:ASND) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ascendis Pharma A/S earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 45.8300524373886 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the media headlines that may have effected Accern’s scoring:
- $570,000.00 in Sales Expected for Ascendis Pharma A/S (ASND) This Quarter (americanbankingnews.com)
- Analysts Anticipate Ascendis Pharma A/S (ASND) Will Announce Earnings of -$0.89 Per Share (americanbankingnews.com)
- Ascendis Pharma A/S Announces Participation in 36th Annual J.P. Morgan Healthcare Conference (finance.yahoo.com)
- Ascendis Pharma A/S (ASND) Receives Average Rating of “Hold” from Brokerages (americanbankingnews.com)
Ascendis Pharma A/S (NASDAQ:ASND) opened at $40.10 on Wednesday. The company has a market capitalization of $1,435.37, a PE ratio of -11.02 and a beta of 0.70. Ascendis Pharma A/S has a 52 week low of $19.21 and a 52 week high of $42.00.
ILLEGAL ACTIVITY WARNING: “Ascendis Pharma A/S (ASND) Receives Daily Media Sentiment Score of 0.20” was first published by Week Herald and is owned by of Week Herald. If you are accessing this news story on another site, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this news story can be viewed at https://weekherald.com/2017/12/27/ascendis-pharma-as-asnd-receives-daily-media-sentiment-score-of-0-20.html.
About Ascendis Pharma A/S
Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.